

MluI
SpeI
BsaAI
EcoICRI
SacI
PvuI
pCMV
SP6
'Amp
pUC
PmlI
BsaAI
XhoI
NotI
PacI
PspOMI
SphI
pA
3'UTR
BsaAI
BsaAI
BsaAI
Eco47III
BbvCI
BsaAI
BsaAI
10000
2000
pCMV-SinRII-GFP
11913 bps
GFP
SGP
8000
4000
NSP 1-3
XbaI
BamHI
NSP 4
6000
ClaI
HpaI
PshAI
AarI
SpeI
SfiI
AflII
Van91I

Fig. 1



Replicon plasmid
GP
SGP
CMV
NSP1
NSP2
NSP3
NSP4
3'
pA
Replicon
Gene of Interest
Structural vector
CMV
Gag (RSV)
Envelope
CMV
VSV-G
RNA containing VLP
mRNA
Protein

Fig. 2



GP
SGP1
SGP2
CMV
NSP1
NSP2
NSP3
NSP4
HLA-DR1
CD80
3'
pA
Replicon
Genes of Interest

Fig. 3



VLP (HLA-DR1/CD80)
100
75
50
25
0
% Survival
Tumors removed
VLP(GFP)
Un-treated
1
2
3
4
5
6
7
8
9
10
11
14
16
18
20
22
24
26
Time (weeks)

Fig. 4



100
75
50
25
0
% Survival
VLP (HLA-DR1/CD80) Treated
Un-treated
2
4
6
Time (weeks)

Fig. 5